載入...
Testing for ROS1 in non-small cell lung cancer: a review with recommendations
Rearrangements of the ROS1 gene occur in 1–2 % of non-small cell lung cancers (NSCLCs). Crizotinib, a highly effective inhibitor of ROS1 kinase activity, is now FDA-approved for the treatment of patients with advanced ROS1-positive NSCLC. Consequently, focus on ROS1 testing is growing. Most laborato...
Na minha lista:
發表在: | Virchows Arch |
---|---|
Main Authors: | , , , , , , , , , , , , , |
格式: | Artigo |
語言: | Inglês |
出版: |
Springer Berlin Heidelberg
2016
|
主題: | |
在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5082594/ https://ncbi.nlm.nih.gov/pubmed/27535289 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00428-016-2000-3 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|